BioSpace News Archive

Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector.

MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the American Society of Clinical Oncology’s upcoming annual meeting.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the management team will present at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. Details are as follows: Date/Time : Tuesday, May 26, 2020 at 12:00 p.m. EDT To access the prese

Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter ended March 31, 2020, and recent developments.

Decision Diagnostics Corp. through its subsidiary Pharma Tech Solutions, Inc. the manufacturers and design specifiers for the GenViro! Covid-19 :15 test professional Swift Kit, announced that it received detailed media coverage for its individual home testing version of the Swift Kit.

Jaguar Health, Inc. announced the voting results from the Annual Meeting of Stockholders of the Company that was held on May 15, 2020.

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that seasoned life sciences executive Dr. Benedikt Timmerman is taking over as the firm’s new Chairman.

The studies in the field of tinnitus research are extremely poor. An article in the Medical Tribune Germany dated November 30, 2019 rightly complains that too little research is being done in the area of tinnitus and that patients feel let down by medicine.

Vir Biotechnology, Inc. announced the publication of research findings from the company’s efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature.